The Nysa Fund (NYSAX), offered by Pinnacle Advisors LLC, is a non-diversified fund that seeks long-term capital growth by primarily investing in publicly traded common stocks of companies. The fund may invest up to 15% of its assets in debt securities that are below investment grade, junk bonds, or unrated bonds.
In 2014, NYSAX was down 42.40% for the year. In addition to poor performance, the fund has high fees (over 5%) and an annual turnover of 128% versus a category average of 64%.
As of September 30, 2014, the fund, managed by Robert Cuculich, had 15.39% of its assets invested in Transluminal Technologies, LLC, a privately held medical device company whose product is not approved for sale, and 12.64% of its assets invested in Ligand Pharmaceuticals Inc (NASDAQ: LGND), amongst a concentrated portfolio of only 23 companies.
If your financial advisor or stockbroker recommended that you invest in the Nysa Fund, you may have options to recover your investment loss. If your advisor failed to fully disclose the risks of investing in the Nysa Fund, then you may have a claim for misrepresentation. If your investment objective was to only invest in safe and stable investments, you may have a claim for unsuitability. If the Nysa Fund made up a large portion of your portfolio, then you may have a claim for over-concentration and lack of diversification. If your advisor purchased this fund without your knowledge, you may have a claim for unauthorized trading. If your advisor purchased this fund on margin, you may have a claim for excessive use of margin and negligence.
The attorneys at Carlson & Associates, P.A., located in Miami, Florida, represent investors who have lost money due to the improper conduct of financial advisors. If you would like to have a free consultation, we can be reached at (305) 372-9700 to discuss your options.